The ‘In The Moment Pilot’. Evaluating methods of in-situ data collection during episodes of injecting drug use to improve opioid overdose response: A protocol paper

Authors: DANIEL O’KEEFE1,2, ASHLEIGH STEWART1,2, NICK SCOTT1,2, PETER HIGGS1,3,4, ALEXIS ROTH5, BEN COCCHIARO6, PAUL DIETZE1,2,3

1Burnet Institute, Melbourne, Australia, 2Monash University, Melbourne, Australia, 3Curtin University, Perth, Australia, 4LaTrobe University, Melbourne, Australia, 5Drexel University, Philadelphia, USA, 6University of Pennsylvania, Philadelphia, USA

Presenter’s email: daniel.okeefe@burnet.edu.au

Introduction and Aims: People who inject drugs are at increased risk of multiple negative health consequences related to injecting drug use. Opioid overdose and blood-borne virus transmission are persistent public health issues among people who inject drugs. Existing research methodologies are often only capable of providing a broad understanding of the circumstances preceding these negative health outcomes. Novel and innovative methods have been proposed to address these limitations, such as biometric monitoring and ecological momentary assessment (EMA).

In this paper, we present the protocol for the In-The-Moment (ITM) pilot, whereby multiple innovative data collection methods will be piloted among a sample of people who inject drugs to better understand the circumstances surrounding injecting drug use and drug overdose.

Design and Methods: Over a three-month study period, 50 participants will be asked to consistently wear a biometric device (similar to a wristwatch) to capture oxygen saturation and pulse rate data. Participants will also be provided with a smartphone to complete short-form, web-based electronic questionnaires following every injecting episode. Finally, participants will also be asked to return needles/syringes previously used to inject with for drug residue testing.

Results: As an exemplar study, the ITM-pilot protocol provides crucial information for the replication of similar work internationally.

Discussions and Conclusions: To better tailor public health interventions to address ongoing drug overdose and injecting risk behaviour, a more comprehensive understanding is needed of the in-situ circumstances surrounding injecting drug use. The ITM-pilot combined data will provide an unprecedented insight into these intractable public health issues.

Disclosure of Interest Statement: PH receives investigator-initiated research funding support from Gilead Sciences and Abbvie. PD has received an investigator-driven grant from Gilead Sciences for unrelated work on hepatitis C and an untied educational grant from Reckitt Benckiser for unrelated work on the introduction of buprenorphine-naloxone into Australia. He has served as an unpaid member on an Advisory Board for an intranasal naloxone product.